Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant Caelyx + cyclophosphamide with or without trastuzumab followed by docetaxel in locally advanced inoperable breast cancer
2008-007951-29Phase 2Completed
- Sponsor
- Herlev Hospital, Onkologisk Afd. R
- Start
- Jan 2009
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegylated liposomal doxorubicin, cyclophosphamide, docetaxel and trastuzumab in breast cancer (2 arms), sponsored by Herlev Hospital, Onkologisk Afd. R. Primary endpoint: Clinical response rate. Started Jan 2009; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-007951-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007951-29.